Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.10 USD
+0.43 (3.68%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $12.09 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.10 USD
+0.43 (3.68%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $12.09 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
AbbVie's HCV Regimen Okayed for Accelerated Assessment
by Zacks Equity Research
AbbVie Inc. (ABBV) recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).